$18.88
1.15[6.49%]
At close: Jun 4
$18.88
0[0.00%]
After Hours: 4:00PM EDT
HUTCHMED (China)
(NASDAQ:HCM)HUTCHMED (China) Stock (NASDAQ:HCM), Analyst Ratings, Price Targets, Predictions
HUTCHMED (China) Ltd has a consensus price target of $35.27, established from looking at the 8 latest analyst ratings. The last 3 analyst ratings were released from Deutsche Bank, Goldman Sachs, and Cantor Fitzgerald on November 24, 2023, November 10, 2023, and September 5, 2023. With an average price target of $29.7 between Deutsche Bank, Goldman Sachs, and Cantor Fitzgerald, there's an implied 57.31% upside for HUTCHMED (China) Ltd from these 3 analyst ratings.
Analyst Firms Making Recommendations1
Deutsche Bank
Goldman Sachs
Cantor Fitzgerald
Jefferies
1calculated from analyst ratings published within the last 3 years
Analyst Ratings for HUTCHMED (China)
| Buy Now | Get Alert | |||||||
|---|---|---|---|---|---|---|---|---|
| 11/24/2023 | Buy Now | 17.06% | Deutsche Bank | Cyrus Ng | $20 → $22.1 | Upgrade | Hold → Buy | Get Alert |
| 11/10/2023 | Buy Now | -9.96% | Goldman Sachs | Paul Choi | $15 → $17 | Maintains | Neutral | Get Alert |
| 09/05/2023 | Buy Now | 164.83% | Cantor Fitzgerald | Louise Chen | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 07/24/2023 | Buy Now | 164.83% | Cantor Fitzgerald | Louise Chen | → $50 | Reiterates | Overweight → Overweight | Get Alert |
| 08/09/2022 | Buy Now | -15.25% | Goldman Sachs | Paul Choi | $14 → $16 | Maintains | Neutral | Get Alert |
| 08/02/2022 | Buy Now | -25.85% | Goldman Sachs | Paul Choi | $16 → $14 | Maintains | Neutral | Get Alert |
| 09/22/2021 | Buy Now | 143.64% | Goldman Sachs | Paul Choi | — | Downgrade | Buy → Neutral | Get Alert |
| 08/03/2021 | Buy Now | 175.42% | Jefferies | Kelly Shi | — | Initiates | → Buy | Get Alert |
FAQ
What is the target price for HUTCHMED (China) (HCM)?
The latest price target for HUTCHMED (China) (NASDAQ: HCM) was reported by Deutsche Bank on November 24, 2023. The analyst firm set a price target for $22.10 expecting HCM to rise to within 12 months (a possible 17.06% upside). 4 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for HUTCHMED (China) (HCM)?
The latest analyst rating for HUTCHMED (China) (NASDAQ: HCM) was provided by Deutsche Bank, and HUTCHMED (China) upgraded their buy rating.
When was the last upgrade for HUTCHMED (China) (HCM)?
The last upgrade for HUTCHMED (China) Ltd happened on November 24, 2023 when Deutsche Bank raised their price target to $22.1. Deutsche Bank previously had a hold for HUTCHMED (China) Ltd.
When was the last downgrade for HUTCHMED (China) (HCM)?
The last downgrade for HUTCHMED (China) Ltd happened on September 22, 2021 when Goldman Sachs changed their price target from N/A to $46 for HUTCHMED (China) Ltd.
When is the next analyst rating going to be posted or updated for HUTCHMED (China) (HCM)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of HUTCHMED (China), and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for HUTCHMED (China) was filed on November 24, 2023 so you should expect the next rating to be made available sometime around November 24, 2024.
Is the Analyst Rating HUTCHMED (China) (HCM) correct?
While ratings are subjective and will change, the latest HUTCHMED (China) (HCM) rating was a upgraded with a price target of $20.00 to $22.10. The current price HUTCHMED (China) (HCM) is trading at is $18.88, which is out of the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.